Lebrikizumab

Unassigned

New Medicines

Atopic dermatitis

Information

New molecular entity
Almirall
Dermira

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Humanised monoclonal antibody that binds to interleukin-13 thereby reducing type 2 inflammation
Atopic eczema is common and the prevalence is increasing. It is seen in 20% of children in developed countries and in developing countries the prevalence is heading towards this figure. In adults, population studies report an overall prevalence of 2-18%.
Atopic dermatitis
Subcutaneous injection